Re: Placebo responses in device studies

Peter J. Goadsby; David W. Dodick; Richard B. Lipton

doi:10.1177/0333102417722498

Re: Placebo responses in device studies

Peter J. Goadsby, David W. Dodick, Richard B. Lipton

Neurology

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1007-1008
Number of pages	2
Journal	Cephalalgia
Volume	38
Issue number	5
DOIs	https://doi.org/10.1177/0333102417722498
State	Published - Apr 1 2018

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1177/0333102417722498

Cite this

@article{1fa2a68c96bc43ba9ef911ae4ed3621d,

title = "Re: Placebo responses in device studies",

author = "Goadsby, {Peter J.} and Dodick, {David W.} and Lipton, {Richard B.}",

note = "Funding Information: Dr Lipton He receives research support from the NIH: 2PO1 AG003949 (Program Director), 5U10 NS077308 (PI), 1RO1 AG042595 (Investigator), RO1 NS082432 (Investigator), K23 NS09610 (Mentor), K23AG049466 (Mentor). He also receives support from the Migraine Research Foundation and the National Headache Foundation. He serves on the editorial board of Neurology and as senior advisor to Headache. He has reviewed for the NIA and NINDS, holds stock options in eNeura Therapeutics and Biohaven Holdings; serves as consultant, advisory board member, or has received honoraria from: American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Colucid, Dr. Reddy{\textquoteright}s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKlein, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, Vedanta. He receives royalties from Wolff{\textquoteright}s Headache, 8th Edition, Oxford Press University, 2009, Wiley and Informa. Funding Information: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Dr. Goadsby reports, unrelated to this note, grants and personal fees from Allergan, Amgen, and Eli-Lilly and Company; and personal fees from Akita Biomedical, Alder Biopharmaceuticals, Avanir Pharma, Cipla Ltd, Dr Reddy{\textquoteright}s Laboratories, eNeura, Electrocore LLC, Novartis, Pfizer Inc, Quest Diagnostics, Scion, Teva Pharmaceuticals, Trigemina Inc., Scion; and personal fees from MedicoLegal work, Journal Watch, Up-to-Date, Massachusetts Medical Society, Oxford University Press; and in addition, has a patent Magnetic stimulation for headache assigned to eNeura.",

year = "2018",

month = apr,

day = "1",

doi = "10.1177/0333102417722498",

language = "English (US)",

volume = "38",

pages = "1007--1008",

journal = "Cephalalgia",

issn = "0333-1024",

publisher = "SAGE Publications Ltd",

number = "5",

}

TY - JOUR

T1 - Re

T2 - Placebo responses in device studies

AU - Goadsby, Peter J.

AU - Dodick, David W.

AU - Lipton, Richard B.

N1 - Funding Information: Dr Lipton He receives research support from the NIH: 2PO1 AG003949 (Program Director), 5U10 NS077308 (PI), 1RO1 AG042595 (Investigator), RO1 NS082432 (Investigator), K23 NS09610 (Mentor), K23AG049466 (Mentor). He also receives support from the Migraine Research Foundation and the National Headache Foundation. He serves on the editorial board of Neurology and as senior advisor to Headache. He has reviewed for the NIA and NINDS, holds stock options in eNeura Therapeutics and Biohaven Holdings; serves as consultant, advisory board member, or has received honoraria from: American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Colucid, Dr. Reddy’s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKlein, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, Vedanta. He receives royalties from Wolff’s Headache, 8th Edition, Oxford Press University, 2009, Wiley and Informa. Funding Information: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Dr. Goadsby reports, unrelated to this note, grants and personal fees from Allergan, Amgen, and Eli-Lilly and Company; and personal fees from Akita Biomedical, Alder Biopharmaceuticals, Avanir Pharma, Cipla Ltd, Dr Reddy’s Laboratories, eNeura, Electrocore LLC, Novartis, Pfizer Inc, Quest Diagnostics, Scion, Teva Pharmaceuticals, Trigemina Inc., Scion; and personal fees from MedicoLegal work, Journal Watch, Up-to-Date, Massachusetts Medical Society, Oxford University Press; and in addition, has a patent Magnetic stimulation for headache assigned to eNeura.

PY - 2018/4/1

Y1 - 2018/4/1

UR - http://www.scopus.com/inward/record.url?scp=85045302066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045302066&partnerID=8YFLogxK

U2 - 10.1177/0333102417722498

DO - 10.1177/0333102417722498

M3 - Letter

C2 - 28747062

AN - SCOPUS:85045302066

VL - 38

SP - 1007

EP - 1008

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 5

ER -

Re: Placebo responses in device studies

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this